Cochrane Review Group

Epilepsy

77 systematic reviews in Epilepsy ask 970 questions. 19.6% have no studies to answer them, 13.9% rest on very low certainty evidence and 32.3% reach moderate or high certainty.

Reviews

Questions

970

current versions

No studies

19.6%

Moderate or high

32.3%

No studies 190 · 19.6%Ungraded 42 · 4.3%Very low 135 · 13.9%Low 289 · 29.8%Moderate 242 · 24.9%High 72 · 7.4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Epilepsy

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Immunomodulatory interventions vs placebo Seizure freedom · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane	no estimate extracted	NR	No studies
Immunomodulatory interventions vs placebo Allergic reactions · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane	no estimate extracted	NR	No studies
Immunomodulatory interventions vs placebo Cognitive effects · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane	no estimate extracted	NR	No studies
Immunomodulatory interventions vs placebo Quality of life · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane	no estimate extracted	NR	No studies
Rapid vs slow withdrawal of antiepileptic drugs Seizure freedom after 1 year of AED withdrawal · people with epilepsy Rapid versus slow withdrawal of antiepileptic drugs (2022) · Cochrane	RR 0.76 [0.58, 1.01]	1 study · 149 participants	Very low
Rapid vs slow withdrawal of antiepileptic drugs Seizure freedom after 2 years of AED withdrawal · people with epilepsy Rapid versus slow withdrawal of antiepileptic drugs (2022) · Cochrane	RR 0.87 [0.58, 1.29]	1 study · 149 participants	Very low
Rapid vs slow withdrawal of antiepileptic drugs Seizure freedom after 5 years of AED withdrawal · people with epilepsy Rapid versus slow withdrawal of antiepileptic drugs (2022) · Cochrane	RR 1.4 [0.54, 3.65]	1 study · 149 participants	Very low
Intervention NR Primary outcomes · patients with stroke Antiepileptic drugs for the primary and secondary prevention of seizures after stroke (2022) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Secondary seizure prophylaxis after stroke · patients with stroke Antiepileptic drugs for the primary and secondary prevention of seizures after stroke (2022) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Secondary outcomes · patients with stroke Antiepileptic drugs for the primary and secondary prevention of seizures after stroke (2022) · Cochrane	no estimate extracted	NR	No studies
Pregabalin vs placebo Adverse effect: headache · drug‐resistant focal epilepsy Pregabalin add‐on for drug‐resistant focal epilepsy (2022) · Cochrane	RR 0.65 [0.45, 0.94]	6 studies · 1850 participants	Very low
Pregabalin vs active comparators 50% or greater reduction in seizure frequency ‐ best‐case analysis · drug‐resistant focal epilepsy Pregabalin add‐on for drug‐resistant focal epilepsy (2022) · Cochrane	RR 1.6 [1.17, 2.19]	3 studies · 1286 participants	Very low

Reviews 77

Antidepressants for people with epilepsy and depression

Maguire, MJ, Marson, AG, et al. · Cochrane Database of Systematic Reviews · 2021

Epilepsy

Thinnest evidence

Reviews 77

Antidepressants for people with epilepsy and depression

Transcranial magnetic stimulation for the treatment of epilepsy

Chloral hydrate as a sedating agent for neurodiagnostic procedures in children

Treatment of epilepsy for people with Alzheimer's disease

Carisbamate add‐on therapy for drug‐resistant focal epilepsy

Medications for daytime sleepiness in individuals with idiopathic hypersomnia

Treatments for seizures in catamenial (menstrual‐related) epilepsy

Zonisamide add‐on therapy for focal epilepsy

Levetiracetam add‐on for drug‐resistant focal epilepsy

Ketogenic diets for drug‐resistant epilepsy

Antiepileptic drugs as prophylaxis for postcraniotomy seizures

Vigabatrin add‐on therapy for drug‐resistant focal epilepsy

Lamotrigine add‐on therapy for drug‐resistant generalised tonic‐clonic seizures

Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy

Rufinamide add‐on therapy for drug‐resistant epilepsy

Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP)

Psychological treatments for people with epilepsy

Oxcarbazepine add‐on for drug‐resistant focal epilepsy

Topiramate add‐on therapy for drug‐resistant focal epilepsy

Tiagabine add‐on therapy for drug‐resistant focal epilepsy

Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review

Clobazam add‐on therapy for drug‐resistant epilepsy

Intravenous immunoglobulins for epilepsy

Losigamone add‐on therapy for focal epilepsy

Sulthiame add‐on therapy for epilepsy